RetinAI is thrilled to introduce our novel method for the segmentation of atrophy with performance matching human experts published in Scientific Reports and developed in collaboration with the Fondation Asile des aveugles, Hôpital ophtalmique Jules-Gonin in Lausanne. Congratulations to both teams for this success!
Full Article - https://www.nature.com/articles/s41598-021-01227-0
Authors: Yasmine Derradji, Agata Mosinska, Stefanos Apostolopoulos, Carlos Ciller, Sandro De Zanet & Irmela Mantel Widmer
We are happy to present our novel method for prediction of continuous atrophy growth for follow-up periods of 4 years and longer in this year's EURETINA 2021. Congratulations to our collaborators and team members for this great poster.
We enable for the first time the creation of atrophy risk maps, which present the risk of retinal regions being affected by the atrophy in the future.
Authors: Agata Mosinska, Anthony Gigon, Stefanos Apostolopoulos, Carlos Ciller, Irmela Mantel Widmer, Sandro De Zanet
RetinAI is proud to be recognized as one of the TOP 100 Swiss Startups for 2021. Check out the ‘Hall of Fame’ on www.top100startups.swiss to see Retinai again in the list this year.
Huge thanks to everyone in the team, to our supporters, and to our partners for believing in us along the way and for supporting us to define the future of Digital Precision Medicine!
'Does real-time artificial intelligence-based visual pathology enhancement of three-dimensional optical coherence tomography scans optimise treatment decision in patients with nAMD? Rationale and design of the RAZORBILL study'
A first of its class international multi-center clinical study to assess the influence of automated 3D OCT scan enrichment with segmentation information on disease activity assessment in patients with nAMD treated with either brolucizumab, ranibizumab or aflibercept.
We are glad to be supporting this initiative together with a leading team of world renown ophthalmologists & Novartis!